InvestorsHub Logo
Followers 52
Posts 4109
Boards Moderated 0
Alias Born 07/03/2005

Re: None

Tuesday, 06/05/2018 1:10:05 PM

Tuesday, June 05, 2018 1:10:05 PM

Post# of 4273
New analysis affirms risk/benefit profile of Synergy's Trulance in CIC; shares up 5%
Jun. 5, 2018 1:02 PM ET|By: Douglas W. House, SA News Editor
A new retrospective risk/benefit analysis from pooled Phase 3 trial data assessing Synergy Pharmaceuticals' (SGYP +4.7%) TRULANCE (plecanatide) and Allergan (AGN +0.8%) and Ironwood Pharmaceuticals' (IRWD -0.5%) LINZESS (linaclotide) in adult patients with chronic idiopathic constipation (CIC) showed the relative advantage of TRULANCE. The data were presented at Digestive Disease Week in Washington, DC.
A metric called "number needed to treat" or NNT, showing the number of patients that need to be treated to show a clinical benefit (low number is better), was comparable between TRULANCE 3 mg and LINZESS 72 mcg and 45 mcg.
Another metric called "number needed to harm" or NNH, showing the number of patients that need to be treated before seeing a detrimental effect (high number is better), favored TRULANCE. Its NNH value was almost 3x higher than its NNT values, implying that treated patients are three times more likely to experience a beneficial effect before experiencing a harmful effect.
The NNH values for LINZESS were lower than the NNT values implying that patients receiving either dose would most likely experience a harmful effect before experiencing a beneficial effect.
The FDA approved TRULANCE for CIC in January 2017.

Hebrews 11:6 And without faith it is impossible to please Him, for he who comes to God must believe that He is and that He is a rewarder of those who seek Him.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.